Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Repurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant APC and TP53 Subpopulations.

Yang M, Schell MJ, Loboda A, Nebozhyn M, Li J, Teer JK, Pledger WJ, Yeatman TJ.

Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1141-1152. doi: 10.1158/1055-9965.EPI-18-1383. Epub 2019 Apr 23.

PMID:
31015202
2.

Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy.

Ayers M, Nebozhyn M, Cristescu R, McClanahan TK, Perini R, Rubin E, Cheng JD, Kaufman DR, Loboda A.

Clin Cancer Res. 2019 Mar 1;25(5):1564-1573. doi: 10.1158/1078-0432.CCR-18-1316. Epub 2018 Nov 15.

PMID:
30442684
3.

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.

Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, Zhang C, Lunceford JK, Joe A, Cheng J, Webber AL, Ibrahim N, Plimack ER, Ott PA, Seiwert TY, Ribas A, McClanahan TK, Tomassini JE, Loboda A, Kaufman D.

Science. 2018 Oct 12;362(6411). pii: eaar3593. doi: 10.1126/science.aar3593. Erratum in: Science. 2019 Mar 1;363(6430):.

4.

A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.

Cook N, Basu B, Smith DM, Gopinathan A, Evans J, Steward WP, Palmer D, Propper D, Venugopal B, Hategan M, Anthoney DA, Hampson LV, Nebozhyn M, Tuveson D, Farmer-Hall H, Turner H, McLeod R, Halford S, Jodrell D.

Br J Cancer. 2018 Mar 20;118(6):793-801. doi: 10.1038/bjc.2017.495. Epub 2018 Feb 13.

5.

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.

Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY; Alliance for Clinical Trials in Oncology and ABTC.

Neuro Oncol. 2018 Mar 27;20(4):546-556. doi: 10.1093/neuonc/nox161.

6.

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, Piha-Paul SA, Yearley J, Seiwert TY, Ribas A, McClanahan TK.

J Clin Invest. 2017 Aug 1;127(8):2930-2940. doi: 10.1172/JCI91190. Epub 2017 Jun 26.

7.

Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.

Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frodin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Watkins DJ.

Int J Cancer. 2017 Jan 15;140(2):431-439. doi: 10.1002/ijc.30453. Epub 2016 Oct 17.

8.

A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.

Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, Monge OR, Lassaletta A, Boldrini E, Pápai Z, Rubino J, Pathiraja K, Hille DA, Ayers M, Yao SL, Nebozhyn M, Lu B, Mauro D.

Pediatr Blood Cancer. 2016 Oct;63(10):1761-70. doi: 10.1002/pbc.26087. Epub 2016 Jun 30.

9.

A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC.

Schell MJ, Yang M, Teer JK, Lo FY, Madan A, Coppola D, Monteiro AN, Nebozhyn MV, Yue B, Loboda A, Bien-Willner GA, Greenawalt DM, Yeatman TJ.

Nat Commun. 2016 Jun 15;7:11743. doi: 10.1038/ncomms11743.

10.

High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide.

Guertin AD, O'Neil J, Stoeck A, Reddy JA, Cristescu R, Haines BB, Hinton MC, Dorton R, Bloomfield A, Nelson M, Vetzel M, Lejnine S, Nebozhyn M, Zhang T, Loboda A, Picard KL, Schmidt EV, Dussault I, Leamon CP.

Mol Cancer Ther. 2016 Aug;15(8):1998-2008. doi: 10.1158/1535-7163.MCT-15-0950. Epub 2016 Jun 2.

11.

A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.

Schell MJ, Yang M, Missiaglia E, Delorenzi M, Soneson C, Yue B, Nebozhyn MV, Loboda A, Bloom G, Yeatman TJ.

Clin Cancer Res. 2016 Feb 1;22(3):734-45. doi: 10.1158/1078-0432.CCR-15-0143. Epub 2015 Oct 7.

12.

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.

Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frödin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Mauro DJ, Watkins DJ.

J Natl Cancer Inst. 2015 Sep 23;107(12):djv258. doi: 10.1093/jnci/djv258. Print 2015 Dec.

PMID:
26405092
13.

Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics.

Geeleher P, Loboda A, Lenkala D, Wang F, LaCroix B, Karovic S, Wang J, Nebozhyn M, Chisamore M, Hardwick J, Maitland ML, Huang RS.

J Natl Cancer Inst. 2015 Aug 21;107(11). pii: djv247. doi: 10.1093/jnci/djv247. Print 2015 Nov.

14.

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.

Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, Ye XS, Do IG, Liu S, Gong L, Fu J, Jin JG, Choi MG, Sohn TS, Lee JH, Bae JM, Kim ST, Park SH, Sohn I, Jung SH, Tan P, Chen R, Hardwick J, Kang WK, Ayers M, Hongyue D, Reinhard C, Loboda A, Kim S, Aggarwal A.

Nat Med. 2015 May;21(5):449-56. doi: 10.1038/nm.3850. Epub 2015 Apr 20.

PMID:
25894828
15.

Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing.

Wong SS, Kim KM, Ting JC, Yu K, Fu J, Liu S, Cristescu R, Nebozhyn M, Gong L, Yue YG, Wang J, Ronghua C, Loboda A, Hardwick J, Liu X, Dai H, Jin JG, Ye XS, Kang SY, Do IG, Park JO, Sohn TS, Reinhard C, Lee J, Kim S, Aggarwal A.

Nat Commun. 2014 Nov 19;5:5477. doi: 10.1038/ncomms6477.

PMID:
25407104
16.

MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.

Booher RN, Hatch H, Dolinski BM, Nguyen T, Harmonay L, Al-Assaad AS, Ayers M, Nebozhyn M, Loboda A, Hirsch HA, Zhang T, Shi B, Merkel CE, Angagaw MH, Wang Y, Long BJ, Lennon XQ, Miselis N, Pucci V, Monahan JW, Lee J, Kondic AG, Im EK, Mauro D, Blanchard R, Gilliland G, Fawell SE, Zawel L, Schuller AG, Strack P.

PLoS One. 2014 Oct 7;9(10):e108371. doi: 10.1371/journal.pone.0108371. eCollection 2014.

17.

Senescence-associated-gene signature identifies genes linked to age, prognosis, and progression of human gliomas.

Coppola D, Balducci L, Chen DT, Loboda A, Nebozhyn M, Staller A, Fulp WJ, Dalton W, Yeatman T, Brem S.

J Geriatr Oncol. 2014 Oct 1;5(4):389-99. doi: 10.1016/j.jgo.2014.08.003. Epub 2014 Sep 11.

PMID:
25220188
18.

Molecular insights into the pathogenesis of Alzheimer's disease and its relationship to normal aging.

Podtelezhnikov AA, Tanis KQ, Nebozhyn M, Ray WJ, Stone DJ, Loboda AP.

PLoS One. 2011;6(12):e29610. doi: 10.1371/journal.pone.0029610. Epub 2011 Dec 28.

19.

Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling.

Coppola D, Nebozhyn M, Khalil F, Dai H, Yeatman T, Loboda A, Mulé JJ.

Am J Pathol. 2011 Jul;179(1):37-45. doi: 10.1016/j.ajpath.2011.03.007. Epub 2011 May 3.

20.

EMT is the dominant program in human colon cancer.

Loboda A, Nebozhyn MV, Watters JW, Buser CA, Shaw PM, Huang PS, Van't Veer L, Tollenaar RA, Jackson DB, Agrawal D, Dai H, Yeatman TJ.

BMC Med Genomics. 2011 Jan 20;4:9. doi: 10.1186/1755-8794-4-9.

21.

cDNA targets improve whole blood gene expression profiling and enhance detection of pharmocodynamic biomarkers: a quantitative platform analysis.

Parrish ML, Wright C, Rivers Y, Argilla D, Collins H, Leeson B, Loboda A, Nebozhyn M, Marton MJ, Lejnine S.

J Transl Med. 2010 Sep 25;8:87. doi: 10.1186/1479-5876-8-87.

22.

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.

Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, Roberts B, Zhang T, Chenard M, Haines B, Andersen J, Nagashima K, Paweletz C, Lynch B, Feldman I, Dai H, Huang P, Watters J.

BMC Med Genomics. 2010 Jun 30;3:26. doi: 10.1186/1755-8794-3-26.

23.

Biomarker discovery: identification of a growth factor gene signature.

Loboda A, Nebozhyn M, Cheng C, Vessey R, Huang P, Dai H, Watters JW.

Clin Pharmacol Ther. 2009 Jul;86(1):92-6. doi: 10.1038/clpt.2009.48. Epub 2009 Apr 22.

PMID:
19387436
24.

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.

Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF Jr, Zwiebel J, Buckner JC.

J Clin Oncol. 2009 Apr 20;27(12):2052-8. doi: 10.1200/JCO.2008.19.0694. Epub 2009 Mar 23. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3262-3.

25.

Diurnal variation of the human adipose transcriptome and the link to metabolic disease.

Loboda A, Kraft WK, Fine B, Joseph J, Nebozhyn M, Zhang C, He Y, Yang X, Wright C, Morris M, Chalikonda I, Ferguson M, Emilsson V, Leonardson A, Lamb J, Dai H, Schadt E, Greenberg HE, Lum PY.

BMC Med Genomics. 2009 Feb 9;2:7. doi: 10.1186/1755-8794-2-7.

26.

VISDA: an open-source caBIG analytical tool for data clustering and beyond.

Wang J, Li H, Zhu Y, Yousef M, Nebozhyn M, Showe M, Showe L, Xuan J, Clarke R, Wang Y.

Bioinformatics. 2007 Aug 1;23(15):2024-7. Epub 2007 May 31.

PMID:
17540678
27.

A 10-gene classifier for distinguishing head and neck squamous cell carcinoma and lung squamous cell carcinoma.

Vachani A, Nebozhyn M, Singhal S, Alila L, Wakeam E, Muschel R, Powell CA, Gaffney P, Singh B, Brose MS, Litzky LA, Kucharczuk J, Kaiser LR, Marron JS, Showe MK, Albelda SM, Showe LC.

Clin Cancer Res. 2007 May 15;13(10):2905-15.

28.

Chromatin profiling of Epstein-Barr virus latency control region.

Day L, Chau CM, Nebozhyn M, Rennekamp AJ, Showe M, Lieberman PM.

J Virol. 2007 Jun;81(12):6389-401. Epub 2007 Apr 4.

29.

Microarray data on gene modulation by HIV-1 in immune cells: 2000-2006.

Giri MS, Nebozhyn M, Showe L, Montaner LJ.

J Leukoc Biol. 2006 Nov;80(5):1031-43. Epub 2006 Aug 29. Review.

PMID:
16940334
30.

Combining multi-species genomic data for microRNA identification using a Naive Bayes classifier.

Yousef M, Nebozhyn M, Shatkay H, Kanterakis S, Showe LC, Showe MK.

Bioinformatics. 2006 Jun 1;22(11):1325-34. Epub 2006 Mar 16.

PMID:
16543277
31.

Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy.

Nebozhyn M, Loboda A, Kari L, Rook AH, Vonderheid EC, Lessin S, Berger C, Edelson R, Nichols C, Yousef M, Gudipati L, Shang M, Showe MK, Showe LC.

Blood. 2006 Apr 15;107(8):3189-96. Epub 2006 Jan 10.

32.

Infection of U937 monocytic cells with Chlamydia pneumoniae induces extensive changes in host cell gene expression.

Virok D, Loboda A, Kari L, Nebozhyn M, Chang C, Nichols C, Endresz V, Gonczol E, Berencsi K, Showe MK, Showe LC.

J Infect Dis. 2003 Nov 1;188(9):1310-21. Epub 2003 Oct 13.

PMID:
14593587
33.

Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma.

Kari L, Loboda A, Nebozhyn M, Rook AH, Vonderheid EC, Nichols C, Virok D, Chang C, Horng WH, Johnston J, Wysocka M, Showe MK, Showe LC.

J Exp Med. 2003 Jun 2;197(11):1477-88.

Supplemental Content

Loading ...
Support Center